Miromatrix Medical Inc.
MIRO · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.02 | 0.58 | -0.10 | 0.00 |
| FCF Yield | -44.77% | -19.01% | -5.07% | -5.28% |
| EV / EBITDA | -2.03 | -3.16 | -14.33 | -17.25 |
| Quality | ||||
| ROIC | -99.98% | -29.88% | -247.54% | -45.37% |
| Gross Margin | 47.56% | -1,412.13% | -974.58% | 0.00% |
| Cash Conversion Ratio | 0.89 | 1.01 | 0.78 | 2.06 |
| Growth | ||||
| Revenue 3-Year CAGR | 173.65% | -49.05% | 359,575.63% | 629,860.52% |
| Free Cash Flow Growth | -52.51% | -122.92% | 3.15% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 0.06 | 3.76 | -0.25 | 0.23 |
| Interest Coverage | -633.66 | -25.07 | -13.41 | -185.84 |
| Efficiency | ||||
| Inventory Turnover | 0.62 | 0.62 | 0.00 | 0.00 |
| Cash Conversion Cycle | -175.48 | 13,126.40 | 808.67 | 328.24 |